AGC
AMED

Angelo Gordon & Co’s Amedisys AMED Stock Holding History

Angelo Gordon & Co’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,000
Closed -$2.32M – 63
2025
Q1 		$2.32M Buy
+25,000
New +$2.3M 0.4% 33
2024
Q1 		– Sell
-26,057
Closed -$2.48M – 64
2023
Q4 		$2.48M Buy
+26,057
New +$2.43M 0.78% 24

Other funds holding AMED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Angelo Gordon & Co's AMED Position: Q2 2025 in Review

Angelo Gordon & Co sold out of Amedisys (AMED) in Q2 2025, closing a stake of 25,000 shares — an estimated $2.32M sold.

Angelo Gordon & Co first reported a position in AMED in Q4 2023 and held it in 2 quarters. The position peaked at $2.48M in Q4 2023. 320 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

  • Angelo Gordon & Co reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
  • Angelo Gordon & Co sold 25,000 Amedisys shares in Q2 2025, an estimated $2.32M.
  • Angelo Gordon & Co first reported a position in Amedisys in Q4 2023 and held it in 2 quarters.
  • Angelo Gordon & Co's Amedisys position peaked at $2.48M in Q4 2023.
  • 320 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Angelo Gordon & Co's 13F filing for Q2 2025, filed 14 Aug 2025.